Sugi Predict

Sugi Predict / Compounds / SCHEMBL1892503

SCHEMBL1892503

SCHEMBL1892503

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2[N+](=O)[O-])c2c1CCN(S(=O)(=O)c1cc(Cl)cc(Cl)c1)C2

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TMEM97 Q5BJF2 4/20 0.44
▸ SIGMAR1 Q99720 4/20 0.44
▸ IGF1R P08069 2/20 0.41
▸ SIRT6 Q8N6T7 5/20 0.38
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ THRB P10828 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ VCAM1 P19320 1/20 0.35
▸ PTPN11 Q06124 1/20 0.35
▸ HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1891150 0.94 HTT (0.40) TMEM97SIGMAR1IGF1RSIRT6MAPT
SCHEMBL1894731 0.92 IGF1R (0.50) IGF1RSIRT6MAPTLMNAPOLB
SCHEMBL1890266 0.92 SIRT6 (0.42) IGF1RSIRT6MAPTLMNAPOLB
SCHEMBL1889278 0.90 MAPT (0.41) IGF1RSIRT6MAPTLMNAPOLB
SCHEMBL1891290 0.89 IGF1R (0.45) IGF1RSIRT6MAPTLMNAPOLB
SCHEMBL1894300 0.89 IGF1R (0.40) IGF1RSIRT6MAPTLMNAPOLB
SCHEMBL1891552 0.89 L3MBTL1 (0.46) IGF1RSIRT6MAPTLMNASMN1; SMN2
SCHEMBL1885344 0.87 IGF1R (0.40) IGF1RSIRT6MAPTLMNAPOLB
SCHEMBL1891125 0.85 SIRT6 (0.43) TMEM97SIGMAR1IGF1RSIRT6MAPT
SCHEMBL1890200 0.85 IGF1R (0.43) IGF1RMAPTLMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 — — US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 — — US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 — — US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 — — US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 — — EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 TMEM97 3217/4885SIGMAR1 4236/4885IGF1R 760/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 TMEM97 3217/4885SIGMAR1 4236/4885IGF1R 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.